Home » Forest Laboratories Announces Additional Settlement Agreement in Bystolic Patent Litigation
Forest Laboratories Announces Additional Settlement Agreement in Bystolic Patent Litigation
Forest Laboratories has settled a case in which it alleged that Amerigen’s ANDA to market generic versions of Bystolic infringed on the company’s patents.
Businesswire
Businesswire
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May